M1 Kliniken (M12) Q3 2025 earnings summary

Executive summary

• Achieved strong EBIT growth of 11% and earnings per share of €0.86 for the first nine months of 2025, driven by efficiency measures and expansion of medical capacities.

• Strategic focus on becoming the world's leading vertically integrated provider of medical aesthetics, including the sale of HAEMATO Pharm GmbH.

Financial highlights

• Group revenue increased by 6.7% to €274.3 million year-over-year; EBITDA rose 9% to €28.2 million.

• EBIT grew 11% to €24.5 million, with an EBIT margin of 8.9%; EBT up 10% to €24.4 million.

• Earnings per share reached €0.86, up from €0.77 in the prior year period.

Outlook and guidance

• Plans to expand the clinic network nationally and internationally, targeting €200–300 million EBIT by 2029 with a sustainable EBIT margin of at least 20%.

• Continued focus on establishing the brand as a global leader in aesthetic medicine.